NEOMED Institute Announces the Appointment of Dr. Youssef Bennani to its Board of Directors

By November 14, 2018No Comments

Montreal, Quebec, November 14, 2018 – NEOMED Institute announced today  that experienced bio-pharmaceutical scientist and executive Dr. Youssef Bennani has joined its Board of Directors.

Dr. Youssef Bennani is currently Chairman of the Board of Domain Therapeutics (France & Canada), and is an independent Board member of Bellus Health (TSX:BLU).  He has over 25 years experience in pharmaceutical R&D leadership and management serving most recently  as Site Head and Vice President of R&D at Vertex Pharmaceuticals Canada Inc.  Prior to this position,  Dr. Bennani spent several years as Vice President Drug Innovation at Vertex’s Headquarters (Boston – MA). He has also held various positions of increasing responsibility in pharmaceutical R&D at Ligand Pharmaceuticals, Abbott Laboratories (now Abbvie) and Athersys. His experience spans multiple therapeutic areas including oncology, neurology, infection, inflammation and renal diseases.  Dr. Bennani has studied in chemistry (PhD, Université de Montréal), business (MBA, LFGSM – Chicago) and corporate governance (ICD.D, McGill-Rotman Schools of Business).

“I am extremely pleased to announce the appointment of Dr. Bennani to our Board of Directors. He brings to the table decades of industrial drug experience across a broad array of therapeutic areas and will employ his scientific and business acumen to helping us to continue to build NEOMED’s reputation as a key actor in Canadian R&D development and commercialization.” declared Dr. Laurence Rulleau, Chairperson of the Board of the NEOMED Institute.

 “I am very excited to join NEOMED’s Board and look forward to collaborating with the experienced and talented board and management team to promote the development and commercialization of Canadian life science discoveries.”  said Dr. Bennani.

 About NEOMED Institute

The NEOMED Institute is a successful and innovative Canadian not-for-profit R&D organization whose mission is to enable and accelerate the commercialization of life science discoveries. NEOMED Institute operates two complementary and integrated divisions: NEOMED Therapeutics in-licenses promising scientific discoveries from Canadian university centres and research institutes and then funds and develops these programs to stages that are attractive for partnering or stand-alone financing; and NEOMED Innovation Centre operates a world-class life sciences ecosystem in Montreal, Quebec hosting 32 life sciences companies employing over 350 people who operate in our two state-of-the-art R&D centres. The NEOMED Institute is funded by pharmaceutical partners, Quebec’s Ministry of the Economy of Science and Innovation, and the Networks of Centres of Excellence of Canada.

For more information, please visit:

Contact information:

NEOMED Institute
Shirley Robinet
Communications Coordinator
7171 Frederick-Banting, Montreal, Quebec, H4S 1Z9
514-375-3334 ext. 111